**Supplementary** **Table 1.**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Antiretroviral agent** | **Arm A**  **Ibalizumab**  **15 mg/kg (n=28)** | | | **Arm B**  **Ibalizumab**  **10 mg/kg (n=27)** | |  | **Placebo Arm**  **(n=27)** | | |
|  | OBR1 | | All regimens | OBR1 | All  regimens |  | OBR1 | | All  regimens |
| NRTI  Abacavir  Didanosine  Emtricitabine  Lamivudine  Stavudine  Tenofovir  Zidovudine | 7 (25) 10 (36)  14 (50)  5 (18)  2 (7)  18 (64)  4 (14) | 9 (32)  11 (39)  14 (50)  8 (29)  2 (7)  20 (71)  5 (18) | | 5 (19)  4 (15)  10 (37)  9 (33)  2 (7)  21 (78)  7 (26) | 6 (21)  7 (26)  12 (44)  11 (41)  3 (11)  22 (81)  9 (33) | 2 (7)  10 (37)  11 (41)  7 (26)  0 (0)  20 (74)  5 (19) | | 3 (11)  11 (41)  11 (41)  11 (41)  2 (7)  20 (74)  5 (19) | |
| NNRTI  Delavirdine  Efavirenz  Nevirapine | 1 (4) 2 (7)  0 (0) | 1 (4)  3 (11)  0 (0) | | 2 (7)  3 (11)  1 (4) | 2 (7)  5 (19)  2 (7) | 0 (0)  7 (26)  0 (0) | | 0 (0)  8 (30)  0 (0) | |
| PI  Atazanavir  Fosamprenavir  Indinavir  Lopinavir/r  Nelfinavir  Ritonavir\*  Saquinavir  Tipranavir | 4 (14) 7 (25)  2 (7)  16 (57)  0 (0)  8 (29)  1 (4)  0 (0) | 6 (21)  7 (25)  2 (7)  16 (57)  1 (4)  11 (39)  1 (4)  2 (7) | | 4 (15)  5 (19)  3 (11)  10 (37)  1 (4)  8 (30)  1 (4)  0 (0) | 7 (26)  8 (30)  3 (11)  12 (44)  1 (4)  12 (44)  2 (7)  1 (4) | 7 (26)  1 (4)  1 (4)  10 (37)  0 (0)  8 (30)  4 (15)  1 (4) | | 8 (30)  2 (7)  2 (7)  11 (41)  0 (0)  11 (41)  5 (19)  3 (11) | |
| Fusion  inhibitor  Enfuvirtide | 0 (0) | 1 (4) | | 0 (0) | 1 (4) | 0 (0) | | 3 (11) | |

All data are presented as N(%)

\*Excludes ritonavir used as pharmacokinetic enhancer.

OBR1, first on-study optimized background regimen; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI, non- nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; /r, with ritonavir boost.